Get Email Updates
To receive email updates about this page, enter your email address:
Volume 2, Number 3—July 1996
Volume 2, Number 3—July 1996 PDF Version [PDF - 6.15 MB - 89 pages]
Molecular Approaches to the Identification
of Unculturable Infectious Agents
PDF Version [PDF - 335 KB - 9 pages]
S. Gao and P. S. MooreView Abstract
New molecular biologic techniques, particularly representational difference analysis, consensus sequence–based polymerase chain reaction, and complementary DNA library screening, have led to the identification of several previously unculturable infectious agents. New agents have been found in tissues from patients with Kaposi's sarcoma, non-A, non-B hepatitis, hantavirus pulmonary syndrome, bacillary angiomatosis, and Whipple's disease by using these techniques without direct culture. The new methods rely on identifying subgenomic fragments from the suspected agent. After a unique nucleic acid fragment belonging to an agent is isolated from diseased tissues, the fragment can be sequenced and used as a probe to identify additional infected tissues or obtain extended portions of the agent's genome. For agents that cannot be cultured by standard techniques, these approaches have proved invaluable for identification and characterization studies. Applying these techniques to other human diseases of suspected infectious etiology may rapidly elucidate novel candidate pathogens.
DNA Vaccines for Emerging Infectious Diseases: What If?
PDF Version [PDF - 41 KB - 8 pages]
R. G. WhalenView Abstract
A novel and powerful method for vaccine research, colloquially known as DNA vaccines, involves the deliberate introduction into tissues of a DNA plasmid carrying an antigen-coding gene that transfects cells in vivo and results in an immune response. DNA vaccines have several distinct advantages, which include ease of manipulation, use of a generic technology, simplicity of manufacture, and chemical and biological stability. In addition, DNA vaccines are a great leveler among researchers around the world because they provide unprecedented ease of experimentation. To facilitate diffusion of information, an Internet site has been established called The DNA Vaccine Web (URL:http://www.genweb.com/Dnavax/dnavax.html). In this review, a brief survey is undertaken of the experimental models and preclinical work on DNA vaccines to contribute to a greater awareness of the possibilities for emerging infectious diseases.
Conjugate Vaccines and the Carriage of Haemophilus influenzae Type b
PDF Version [PDF - 37 KB - 7 pages]
M. L. Barbour and D. PhilView Abstract
Pharyngeal carriage of Haemophilus influenzae type b (Hib) is important in the transmission of Hib organisms, the pathogenesis of Hib disease, and the development of immunity to the bacterium. The remarkable success of current vaccination programs against Hib has been due in part to the effect of conjugate Hib vaccines in decreasing carriage of Hib. This review explores evidence for this effect, and discusses the possible mechanisms of the mucosal influence of Hib conjugate vaccines.
Application of Molecular Techniques
to the Diagnosis of Microsporidial Infection
PDF Version [PDF - 1.09 MB - 9 pages]
D. P. Fedorko and Y. M. HijaziView Abstract
Microsporidia are now recognized as important pathogens of AIDS patients; the ability of these parasites to cause disease in immunocompetent persons is still being elucidated. Improved diagnostic tests for microsporidial infection are continually being sought for establishing diagnosis in order to avoid laborious electron microscopy studies that require invasively acquired biopsy specimens. Modified trichrome or chemofluorescent stains are useful for detecting microsporidia in bodily fluids and stool specimens, but they do not allow for speciation of microsporidia. Polymerase chain reaction with specific primers will allow the detection and speciation of microsporidia in biopsy tissue, bodily fluids, and stool specimens.
Coccidioidomycosis: A Reemerging Infectious Disease
PDF Version [PDF - 683 KB - 8 pages]
T. N. Kirkland and J. FiererView Abstract
Coccidioides immitis, the primary pathogenic fungus that causes coccidioidomycosis, is most commonly found in the deserts of the southwestern United States and Central and South America. During the early 1990s, the incidence of coccidioidomycosis in California increased dramatically. Even though most infections are subclinical or self-limited, the outbreak is estimated to have cost more than $66 million in direct medical expenses and time lost from work in Kern County, California, alone. In addition to the financial loss, this pathogen causes serious and life-threatening disseminated infections, especially among the immunosuppressed, including AIDS patients. This article discusses factors that may be responsible for the increased incidence of coccidioidomycosis (e.g., climatic and demographic changes and the clinical problems of coccidioidomycosis in the immunocompromised) and new approaches to therapy and prevention.
Antibody-Based Therapies for Emerging Infectious Diseases
PDF Version [PDF - 345 KB - 9 pages]
A. CasadevallView Abstract
In the 19th century, it was discovered that immune sera were useful in treating infectious diseases. Serum therapy was largely abandoned in the 1940s because of the toxicity associated with the administration of heterologous sera and the introduction of effective antimicrobial chemotherapy. Recent advances in the technology of monoclonal antibody production provide the means to generate human antibody reagents and reintroduce antibody therapies, while avoiding the toxicities associated with serum therapy. Because of the versatility of antibodies, antibody-based therapies could, in theory, be developed against any existing pathogen. The advantages of antibody-based therapies include versatility, low toxicity, pathogen specificity, enhancement of immune function, and favorable pharmacokinetics; the disadvantages include high cost, limited usefulness against mixed infections, and the need for early and precise microbiologic diagnosis. The potential of antibodies as anti-infective agents has not been fully tapped. Antibody-based therapies constitute a potentially useful option against newly emergent pathogens.
HIV-1 Group O Virus Identified for the First Time in the United States
PDF Version [PDF - 38 KB - 4 pages]
M. A. Rayfield et al.
Two Morbilliviruses Implicated in Bottlenose Dolphin Epizootics
PDF Version [PDF - 26 KB - 4 pages]
J. K. Taubenberger et al.
An Outbreak of Spotted Fever Rickettsiosis in U.S. Army Troops Deployed to Botswana
B. L. Smoak et al.
A Highly Heterogeneous HIV-1 Epidemic in the Central African Republic
PDF Version [PDF - 50 KB - 3 pages]
M. Massanga et al.
Legionella-Like Amebal Pathogens––Phylogenetic Status and Possible Role in Respiratory Disease
PDF Version [PDF - 378 KB - 6 pages]
A. Adeleke et al.
Role of Enterovirus 71 in Acute Flaccid Paralysis After the
Eradication of Poliovirus in Brazil
PDF Version [PDF - 19 KB - 3 pages]
E. E. da Silva et al.
Sentinel Surveillance for Yellow Fever in Kenya, 1993 to 1995
PDF Version [PDF - 371 KB - 3 pages]
E. J. Sanders et al.
Serologic Evidence for the Presence in Pteropus Bats of a Paramyxovirus Related to Equine Morbillivirus
PDF Version [PDF - 15 KB - 2 pages]
P. L. Young et al.
Bancroftian Filariasis Distribution and Diurnal Temperature Differences in the Southern Nile Delta
PDF Version [PDF - 366 KB - 2 pages]
D. F. Thompson et al.
Acute Cervical Lymphadenopathy
PDF Version [PDF - 13 KB - 1 page]
M. B. Pasticci et al.
AIDS: Déjà Vu in Ancient Egypt?
PDF Version [PDF - 32 KB - 1 page]
R. J. Ablin
About the Cover
News and Notes
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
Get Email Updates
To receive email updates about this page, enter your email address:
- Page created: September 07, 2011
- Page last updated: September 07, 2011
- Page last reviewed: September 07, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)